Ujjal Didar Singh Sekhon/LinkedIn
Jul 28, 2026, 08:28
Ujjal Didar Singh Sekhon: Exploring SynthoPlate Under P2Y12 Blockade
Ujjal Didar Singh Sekhon, Director of Research Development at Haima Therapeutics, shared a post on LinkedIn:
“ISTH 2026 was a privilege to be part of: pathbreaking research, illuminating conversations, and a dose of Paris on top.
I was honored to present our work advancing SynthoPlate through models of P2Y12 blockade.
A huge thanks to the Haima team behind this milestone, and to the colleagues who came by with questions and suggestions that will sharpen what comes next.”
Stay updated with Hemostasis Today.
-
Jul 28, 2026, 09:06Payal Desai: Highlights from the NASCC 2026 Sickle Cell Workshop
-
Jul 28, 2026, 08:43Flora Peyvandi։ Acquired Hemophilia A – An Illustrated Review Based on French Guidelines
-
Jul 28, 2026, 08:27Sujeet Katiyar: You Share Patient Data with Your TPA. Where Is the Contract?
-
Jul 28, 2026, 07:50Mihail Celeski: Personalizing Anticoagulant Therapy for Frail Patients With Atrial Fibrillation
-
Jul 28, 2026, 07:36Ifeanyichukwu Ifechidere: What If the Test We’ve Trusted for Decades Has Been Telling Us Half the Story?
-
Jul 28, 2026, 07:10Wolfgang Miesbach: How Safe Is AAV Gene Therapy?
-
Jul 28, 2026, 06:59Fiona Robinson: New MASAC Recommendations for Iron Deficiency – Live Webinar
-
Jul 28, 2026, 06:49Vera Ghali: What Else Do Platelets Do Besides Clotting?
-
Jul 28, 2026, 02:54Joseph R. Shaw: Why Stroke Occurs Despite Anticoagulation